Jazz Pharmaceuticals
JAZZ
389 hedge funds and large institutions have $7.77B invested in Jazz Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 118 increasing their positions, 157 reducing their positions, and 56 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more capital invested
Capital invested by funds: $5.75B → $7.77B (+$2.01B)
14% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 56
13% more call options, than puts
Call options by funds: $112M | Put options by funds: $99.9M
4% more ownership
Funds ownership: 94.33% → 98.32% (+4%)
1% more funds holding
Funds holding: 384 → 389 (+5)
25% less repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 157
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$264M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$147M |
| 3 |
State Street
Boston,
Massachusetts
|
+$82.3M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$55.2M |
| 5 |
Holocene Advisors
New York
|
+$42.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$78.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.9M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$47.6M |
| 4 |
Millennium Management
New York
|
-$33.8M |
| 5 |
Two Sigma Investments
New York
|
-$31.4M |
JAZZ Hedge Fund Activity: Q3 2020 in Review
389 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2020, worth a combined $7.77B — up 35% from $5.75B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new JAZZ positions and 56 closed out — a net gain of 8 holders — while 118 added to existing stakes and 157 trimmed.
The largest buyer was BlackRock, adding an estimated $264M. The largest seller was AQR Capital Management, cutting an estimated $78.2M.
- 389 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2020, up from 384 in Q2 2020.
- Funds reported $7.77B of Jazz Pharmaceuticals stock for Q3 2020, up 35% quarter-over-quarter.
- 64 funds opened new Jazz Pharmaceuticals positions in Q3 2020 and 56 closed out, a net change of +8 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2020 was BlackRock, an estimated $264M added.
- The largest Jazz Pharmaceuticals seller in Q3 2020 was AQR Capital Management, an estimated $78.2M sold.
Based on aggregated 13F filings for Q3 2020.